Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Netanasvir on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Netanasvir is an oral antiviral capsule for chronic hepatitis C, developed in China by the HEC (Dongyangguang) group. The licence holder is Sunshine Lake Pharma, and in China it is sold as 东卫卓® (Chinese name 磷酸萘坦司韦胶囊). It is one half of a two-medicine course: it is always taken with encofosbuvir tablets from the same group, once a day for 12 weeks.
China's National Medical Products Administration (NMPA) approved it in February 2025 as a Class 1 innovative drug, for adults with:
It is a prescription liver medicine and should be used under a hepatologist or gastroenterologist.
Netanasvir blocks NS5A, a protein the hepatitis C virus needs to copy itself and to build new virus particles. Its partner, encofosbuvir, blocks a different target, the NS5B polymerase enzyme. The company describes netanasvir as a second-generation NS5A inhibitor that is not broken down by the liver's CYP enzymes, which is expected to mean fewer clashes with other medicines.
Approval rested on a phase 2/3 study in China (NCT05395416) of netanasvir plus encofosbuvir for 12 weeks. According to the company's reimbursement filings, 95% of patients were cured overall (no detectable virus 12 weeks after the last dose, called SVR12). Cure rates were 99% for genotype 1, 99% for genotype 2, 78% for genotype 3 and 92% for genotype 6, and 92.3% in people with compensated cirrhosis. China's drug review centre reported an SVR12 of 94.1% in the double-blind part of the phase 3 study, and found that viral load, cirrhosis and earlier interferon treatment made no meaningful difference to the result.
A missed capsule should be taken the same day as soon as you remember. If the day has gone, take the next one at the normal time; never take two to make up. No dose change is needed for older people, for compensated cirrhosis (Child-Pugh A) or for mild kidney problems.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Never used alone: netanasvir is approved only together with encofosbuvir, so the warnings for both medicines apply throughout the course.
Side effects: across the phase 2 and 3 studies (442 patients on the combination), side effects affected 41.0% of patients compared with 31.3% on placebo, and most were mild or moderate. Those seen in at least 5% were raised uric acid, raised cholesterol and raised triglycerides. A few changes, such as raised blood creatinine and urea, were seen only in the treatment group. Safety in pregnancy and breastfeeding is not covered in the published summary, so discuss this with your doctor before starting.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The capsules can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and we found no approval by the US FDA or the European Medicines Agency.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. We arrange netanasvir and encofosbuvir together so the full 12-week course arrives as one plan. You can also read about Alfosbuvir, another hepatitis C medicine approved in China.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. Each box holds 28 capsules of 0.1 g (4 strips of 7), which is four weeks of treatment, so a 12-week course needs 3 boxes, alongside 6 boxes of encofosbuvir. The capsules stay in their sealed original packs, are stored as directed on the pack, and travel under temperature-controlled shipping. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating clinic on a valid specialist's prescription.
Liver specialists in Delhi can begin the request for both medicines at once, with dispatch from our New Delhi base.
We deliver the full three-month supply to patients and clinics in Mumbai, so the daily doses never run short.
Gastroenterologists in Bangalore can send the genotype report and prescription to start a named-patient import.
Patients in Chennai can receive the capsules and tablets together at home or at the liver clinic.
Hyderabad patients get clear updates on documents, quote and delivery date before anything is shipped.
For Kolkata and eastern India, deliveries are timed to the treatment start date set by the doctor.
Patients in Pune can use the same documented process, with every step shared in writing.
Doctors in Ahmedabad can arrange this combination for adults with genotype 1, 2, 3 or 6 hepatitis C.
Serves Punjab, Haryana and Himachal Pradesh, delivering to the patient or the treating hospital.
Patients across Rajasthan can be supplied without travelling, provided the import is in their name.
We coordinate supply for patients treated at liver and gastroenterology clinics across Uttar Pradesh.
Patients in Kochi and the rest of Kerala can have the whole course delivered in one planned shipment.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
